Silexion Therapeuticsは 初期開発段階にある RNAiがん治療を進めているため 株価が2.81ドル近くで 季度損失を報告した. Silexion Therapeutics reported a quarterly loss, with its stock near $2.81, as it advances RNAi cancer therapies in early development.

Silexion Therapeuticsは,毎株2.88ドルの四半期損失を報告し,その株式は平均より軽い取引量で0.01ドル下げて2.81ドルで終了しました. Silexion Therapeutics reported a quarterly loss of $2.88 per share, with its stock closing at $2.81, down $0.01 on lighter-than-average trading volume. 8. 7000万ドルで評価される同社は,LOCRプラットフォームを用いたRNAベースのがん療法に焦点をあて,商業製品を持たずに,早期開発を続けている. The company, valued at $8.77 million, remains in early development with no commercial products, focusing on RNAi-based cancer therapies using its LODER platform. 候補者のSG12D-LODERは すい臓がんの臨床試験を終えました プロステート-LOCRとGBM-LOCRは前期の段階にあります。 Its lead candidate, SiG12D-LODER, has completed Phase I trials for pancreatic cancer, while Prostate-LODER and GBM-LODER are in pre-clinical stages. 分析官は混ざり合いの評価を維持しており,その結果,合意の"保留"と平均価格目標の75.00ドルを目標とする. Analysts maintain a mixed rating, resulting in a consensus "Hold" and a $75.00 average price target.